

Cardinal Health Inc. (CAH)

\$53.06 (As of 08/10/20)

Price Target (6-12 Months): **\$56.00**

Long Term: 6-12 Months

Zacks Recommendation:

Neutral

(Since: 05/11/20)

Prior Recommendation: Outperform

Short Term: 1-3 Months

Zacks Rank: (1-5)

3-Hold

Zacks Style Scores:

VGM:A

Value: B

Growth: B

Momentum: B

Summary

Cardinal Health exited the fiscal fourth quarter on a mixed note, wherein earnings surpassed the consensus mark, while revenues missed the same. The company witnessed decline in revenues in both its segments in the quarter under review. Nonetheless, the Medical segment delivered profit in the quarter. Apart from these, the company's extension of agreements with CVS Health and buyout of mscrypts are positives. The company reaffirmed fiscal year 2020 outlook, which instills investor optimism. It also anticipates adjusted earnings per share to range between \$5.25 and \$5.65 in fiscal 2021. Shares of Cardinal Health outperformed the industry in a year's time. However, contraction in both gross and operating margins remains a woe. Intense competition and customer concentration are other concerns.


Price, Consensus & Surprise



Data Overview

52 Week High-Low	\$60.69 - \$39.05
20 Day Average Volume (sh)	2,310,779
Market Cap	\$15.5 B
YTD Price Change	4.9%
Beta	0.99
Dividend / Div Yld	\$1.94 / 3.7%
Industry	Medical - Dental Supplies
Zacks Industry Rank	Top 43% (109 out of 253)

Sales and EPS Growth Rates (Y/Y %)



Last EPS Surprise	14.3%
Last Sales Surprise	-1.0%
EPS F1 Est- 4 week change	2.0%
Expected Report Date	11/05/2020
Earnings ESP	3.6%
P/E TTM	9.7
P/E F1	9.9
PEG F1	1.6
P/S TTM	0.1

Sales Estimates (millions of \$)

	Q1	Q2	Q3	Q4	Annual*
2022	40,214 E	43,160 E	41,865 E	41,574 E	167,623 E
2021	38,148 E	41,350 E	39,586 E	40,197 E	159,284 E
2020	37,341 A	39,735 A	39,157 A	36,689 A	152,922 A

EPS Estimates

	Q1	Q2	Q3	Q4	Annual*
2022	\$1.24 E	\$1.47 E	\$1.67 E	\$1.29 E	\$5.81 E
2021	\$1.12 E	\$1.42 E	\$1.56 E	\$1.24 E	\$5.37 E
2020	\$1.27 A	\$1.52 A	\$1.62 A	\$1.04 A	\$5.45 A

*Quarterly figures may not add up to annual.

The data in the charts and tables, including the Zacks Consensus EPS and Sales estimates, is as of 08/10/2020. The reports text is as of 08/11/2020.

Overview

Headquartered in Dublin, OH, Cardinal Health Inc. is a nation-wide drug distributor and provider of services to pharmacies, healthcare providers and manufacturers. The company has two reporting segments – Pharmaceutical and Medical.

The Pharmaceutical segment is the second largest pharmaceutical distributor in the United States and the largest nuclear pharmacy. Its products and services include pharmaceutical distribution, manufacturer and specialty services, and nuclear and pharmacy services. This segment also offers “specialty pharmaceutical products and services”, which supplies (1) oncology, rheumatology, urology and other pharmaceutical products to physician offices; (2) human plasma products and specialty pharmaceutical products to hospitals and other healthcare providers; (3) consulting and other services to pharmaceutical manufacturers, third party payors and healthcare providers.


The Medical segment manufactures products such as single-use surgical drapes, gowns and apparel; exam and surgical gloves; and fluid suction and collection systems and offers sterile and non-sterile procedure kits. These products are sold directly or distributed via third-party sources in the U.S., Canada, Europe, South America and the Asia/Pacific.

FY20 at a Glance

In fiscal 2020, Cardinal Health registered adjusted earnings of \$5.45 per share, up 3.2% on a year-over-year basis. Revenues increased 5.1% on a year-over-year basis to \$152.9 billion. Delving deeper into the segmental revenue details, Pharmaceutical (89.9% of net revenues) increased 6% to \$137.49 billion in fiscal 2019. Medical revenues (10.1% of net revenues) fell 1% on a year-over-year basis to \$15.44 billion.

Important Acquisitions & Divestments

On Feb 1, 2018, Cardinal Health announced the divestiture of its Cardinal Health China business to Shanghai Pharmaceuticals Holding Co., Ltd. for \$1.2 billion.



Reasons To Buy:

- ▲ **Share Price Movement:** Over the past year, shares of Cardinal Health gained 21.2%, against the industry's decline of 1.5%. Pharmaceutical segment, broad product portfolio and prudent acquisitions continue to drive the stock.
- ▲ **Cost Savings:** In terms of costs, Cardinal Health announced in fourth-quarter fiscal 2019 earnings call that it anticipates incremental cost savings of \$130 million associated with actions intended to optimize and simplify its operating model and cost structure. In the fiscal first quarter, the company reaffirmed the same. The company benefited from this and exceeded its enterprise cost savings target for fiscal 2020.

Cardinal Health's diversified portfolio represent significant long-term opportunities. Further, the company follows an acquisition-driven strategy.

- ▲ **Pharmaceutical Segment to Drive Growth:** Cardinal Health's Pharmaceutical segment is the second largest pharmaceutical distributor in the United States. The segment's products and services comprise pharmaceutical distribution, manufacturer and specialty services, and nuclear and pharmacy services, which are expected to majorly drive the quarters ahead. For the past few quarters, the segment has been acting as a key catalyst when it comes to driving growth. However, in the fiscal fourth quarter, pharmaceutical revenues dipped 0.5% to \$33.24 billion on a year-over-year basis. The downside can primarily be attributed to lower pharmaceutical demand on account of accelerated fiscal third-quarter sales associated with the COVID-19 pandemic. Moreover, Pharmaceutical witnessed a decline of 19.7% in profits to \$359 million. An adverse anticipated COVID-19 impact resulted in volume decline that primarily affected Nuclear and Precision Health Solutions and the company's generics program. Also, Pharmaceutical Distribution customer contract renewals weighed on the performance.

Nonetheless, elective procedures and physician office visits are expected to recover to pre-COVID 19 levels exiting fiscal 2021, with a more substantial impact in the first half of the year. This might reflect on the segment's performance in that period.

For fiscal 2021, the company expects Pharmaceutical segment to witness mid-single digit percentage growth in revenues and low-single digit percentage growth with respect to profit. Higher contribution from key growth areas — Specialty and Connected Care — and sustained market dynamics withing its generics program are anticipated to bolster the segment.

- ▲ **Diversified Product Portfolio:** Cardinal Health's Medical and Pharmaceutical offerings provide the company with a competitive edge in the niche space. The company offers industry expertise and an expanding portfolio of safe products. For example, Cardinal Health's Bathroom Safety, Mobility, and Exam Room Equipment products are exclusively designed for both patients and care givers. With a variety of products ranging from wheelchairs and crutches to exam room tables and commodes, Cardinal Health offers the right mix of medical equipment. Cardinal Health's ECG Monitoring Electrodes offer quality performance and are neoprene-free, lead-free and mercury-free. These are not made with natural rubber latex, and are highly exclusive in the markets.

The company maintains its continued focus in evolving growth areas with investments and partnerships in Specialty, at Home and Services.

- ▲ **Acquisition Drives Growth:** Cardinal Health follows an acquisition-driven strategy and continues to focus on investment in key growth businesses to gain market traction and boost profits. In recent past, Clayton, Dubilier & Rice and Cardinal Health jointly invested in Brentwood, Tennessee-based naviHealth. Cardinal Health sold a 55 percent stake in naviHealth to the New York City-based private equity firm Clayton Dubilier & Rice (CD&R). naviHealth has always been a strong performer for Cardinal Health. Management at Cardinal Health announced that the company is likely to have a competitive edge in the MedTech space with CD&R as a partner. Notably, in the fiscal fourth quarter, Cardinal Health completed the divestiture of its remaining equity interest in naviHealth.

In 2019, Cardinal Health acquired mscripts, a company that specializes in delivering patient adherence and engagement solutions via an innovative, user-friendly mobile and web-based health management platform.

- ▲ **Cushioned Against Macroeconomic Sluggishness:** Large-cap, diversified healthcare distributors such as Cardinal Health are relatively insulated from macroeconomic uncertainty and a weak economy. Cardinal Health is one of the largest distributors of pharmaceuticals and medical supplies. It has a diversified product portfolio, which is a hedge against the risk of sales shortfall in testing times. In fiscal 2019, Cardinal Health's focused on taking the necessary steps to address the changing industry dynamics to position the pharma distribution business for a long-term growth.

The company's generics business continues to show healthy growth, supported by a solid customer base, significant scale of operation and the competence to source products from a complex and global supply network. Cardinal Health has rationalized the number of generic suppliers. In addition, the company has expanded relationships with generic manufacturers that include several benefits like higher service levels, greater clarity on generic cost of goods sold, and a more consistent product supply with fewer disruptions.

- ▲ **Long-term Supply Agreements Buoy Optimism:** Cardinal Health is also pursuing growth via joint ventures and long-term supply agreements with several firms. The company entered a long-term strategic agreement with Henry Schein, under which the latter purchased Cardinal Health's medical supplies for physician practices. The collaboration is expected to drive core sales and prove accretive to Cardinal Health's earnings in the long term.

The signing of a 15-year agreement with Bayer Healthcare for the contract manufacturing of Xofigo is significantly positive. In our opinion, this will help the company leverage its expertise in the nuclear pharmacy industry to expand access to a therapeutic agent and increase the use of radiopharmaceuticals in the U.S. and Canada. The Red Oak Sourcing joint venture with CVS Health, which will negotiate generic pharmaceutical supply contracts on behalf of both companies, also holds significant long-term prospects for Cardinal Health. Cardinal Health extended agreements with CVS Health to distribute pharmaceuticals to retail pharmacies and distribution centers through Jun 30, 2023. In fact, with the recent renewals of CVS Health and Kroger, Cardinal Health now has contracts with three of its largest customers for the next four years.

- ▲ **Strong Liquidity Position:** Cardinal Health exited the fiscal fourth quarter with cash and cash equivalents of \$2.77 billion, compared with \$2.33 billion in the previous quarter. Meanwhile, long-term debt was \$6.77 billion, a slight increase from the \$6.75 billion sequentially. The long-term debt level is significantly higher than the quarter's cash and cash equivalent level. However, we can see that the current debt level

of \$10 million in the quarter, significantly down from \$508 million sequentially, is in fact way lower than the short-term cash level. This is good news in terms of the company's solvency level as, at least during the year of economic downturn, the company has sufficient cash for debt repayment.

Moreover, the company has robust cash flow trends. In the fiscal fourth quarter, the company generated \$240 million of operating cash flow, thereby indicating its continued commitment toward maintaining a robust balance sheet. Per management, the company returned over \$900 million to shareholders through dividends and share buybacks. Also, Cardinal Health boosted its balance sheet by paying down \$1.4 billion of long-term debt.

Reasons To Sell:

▼ **Weak Trends:** In the fiscal fourth quarter, gross profit declined 5% year over year to \$1.59 billion. As a percentage of revenues, gross margin in the reported quarter was 4.3%, down 20 basis points (bps) on a year-over-year basis. The company also reported operating income of \$270 million in the quarter under review, down 20.1% from the year-ago quarter. As a percentage of revenues, operating margin in the reported quarter was 0.7%, down 10 bps on a year-over-year basis.

Pharmaceutical segment witnessed a decline of 19.7% in profits to \$359 million. An adverse anticipated COVID-19 impact resulted in volume decline that primarily affected Nuclear and Precision Health Solutions and the company's generics program. Further, Pharmaceutical Distribution customer contract renewals weighed on the performance.

In the fiscal fourth quarter, revenues at the Medical segment declined 13% to \$3.45 billion attributable to negative impact of cancelled or deferred elective procedures associated with the COVID-19 pandemic, especially on products and distribution.

▼ **Probabilities of Loss of a Major Customer:** Cardinal Health faces the risk of losing considerable business in case of loss of a major customer, which in turn will severely impair its revenues in the future. In this regard, post the establishment of a generic sourcing joint venture with CVS Caremark in 2014, Cardinal Health largely depends on the former for over 20% of its revenues. Collectively, five of Cardinal Health's main customers, including CVS, accounted for as much as 40% of its revenues.

▼ **Group Purchasing Organizations:** Cardinal Health derives a significant quantum of revenues through agreements with group purchasing organizations (GPOs). These organizations act as agents that negotiate vendor contracts on behalf of their members. The company's largest GPO agents are Asembia, HealthTrust, Innovatix, Intalere, Premier Purchasing Partners, and six more. These GPOs accounted for a significant amount of Cardinal Health's revenues. Loss of relationship with either of these agents will severely affect the company's sales. In addition, some GPOs sell products that compete with distributors.

▼ **Integration Risks:** Cardinal Health continues to acquire a large number of companies. While this improves the company's revenue opportunities, it adds to integration risks. The Cordis acquisition was financed through a combination of debt and cash and the \$1 billion debt financing increased leverage in the near term.

▼ **Cutthroat Competition in MedTech Space:** Cardinal Health faces tough competition in each of its business segments. For example, its pharmaceutical supply chain business faces competition from McKesson and AmerisourceBergen as well as several smaller medical-surgical distributors such as Henry Schein and Owens & Minor. Moreover, the medical device market is a mature one compared to Cardinal Health's pharmaceutical business. Although Cordis has significant brand presence, we believe growing competition will hurt Cardinal Health's medical segment's margins in the near term.

Cardinal Health has been facing sluggishness in the exam-gloves unit lately. Further, cutthroat competition in the niche space is a headwind.

Last Earnings Report

Cardinal Health Q4 Earnings Top Estimates, Revenues Lag

Cardinal Health, Inc. reported fourth-quarter fiscal 2020 adjusted earnings of \$1.04 per share, which surpassed the Zacks Consensus Estimate of 91 cents by 14.3%. However, the bottom line declined 6.3% year over year.

For the fiscal 2020, the company reported adjusted EPS of \$5.45, which outpaced the Zacks Consensus Estimate by 3%. The figure improved 3.2% from the year-ago period.

Quarter Ending 06/2020

Report Date	Aug 06, 2020
Sales Surprise	-0.99%
EPS Surprise	14.29%
Quarterly EPS	1.04
Annual EPS (TTM)	5.45

Revenue Details

Revenues declined 1.8% on a year-over-year basis to \$36.69 billion. The top line also missed the Zacks Consensus Estimate by 0.9%.

For fiscal 2020, the company's revenues were \$152.9 billion, up 5.1% from the year-ago period. The metric, however, lagged the consensus mark by 0.3%.

Segmental Analysis

Pharmaceutical Segment

In the fiscal fourth quarter, pharmaceutical revenues dipped 0.5% to \$33.24 billion on a year-over-year basis. The downside was primarily due to lower pharmaceutical demand on account of accelerated fiscal third-quarter sales associated with the COVID-19 pandemic.

Pharmaceutical witnessed a decline of 19.7% in profits to \$359 million. An adverse anticipated COVID-19 impact resulted in volume decline that primarily affected Nuclear and Precision Health Solutions and the company's generics program. Also, Pharmaceutical Distribution customer contract renewals weighed on the performance.

Medical Segment

In the quarter under review, revenues at this segment declined 13% to \$3.45 billion attributable to negative impact of cancelled or deferred elective procedures associated with the COVID-19 pandemic, especially on products and distribution.

Medical segment profit improved 23.7% to \$120 million driven by benefits from cost savings initiatives and the beneficial comparison to a supplier-related charge in the previous year. However, adverse impact of the pandemic, particularly on products and distribution partially offset the upside.

Margin Analysis

Gross profit declined 5% year over year to \$1.59 billion.

As a percentage of revenues, gross margin in the reported quarter was 4.3%, down 20 basis points (bps) on a year-over-year basis.

Distribution, selling, general and administrative expenses totaled \$1.14 billion, down 2.7% year over year.

The company reported operating income of \$270 million in the quarter under review, down 20.1% from the year-ago quarter. As a percentage of revenues, operating margin in the reported quarter was 0.7%, down 10 bps on a year-over-year basis.

Financial Update

The company exited the quarter with cash and cash equivalents of \$2.77 billion, up 18.9% sequentially.

Net cash from operating activities totaled \$240 million at end of the fiscal fourth quarter, compared with \$506 million in the year-ago quarter.

2021 Guidance

The company anticipates adjusted earnings per share to range between \$5.25 and \$5.65. The Zacks Consensus Estimate is pegged at \$5.30 per share (the fiscal 2021 EPS outlook takes into account an incremental net headwind associated with the COVID-19 pandemic of a similar year-over-year magnitude as witnessed in fiscal 2020).

Valuation

Cardinal Health's shares are up 4.9% and 21.2% in the year-to-date period and trailing 12-month periods, respectively. Stocks in the Zacks sub-industry and Zacks Medical sector are up 6.4% and 1% in the year-to-date period, respectively. Over the past year, the Zacks sub-industry are down 1.5% while that in the sector are up 9.1%.

The S&P 500 index is up 3.9% in the year-to-date period and 16.4% in the past year.

The stock is currently trading at 9.9X Forward 12-months earnings, which compares to 19.1X for the Zacks sub-industry, 22.4X for the Zacks sector and 22.8X for the S&P 500 index.

Over the past five years, the stock has traded as high as 16.8X and as low as 7.5X, with a 5-year median of 11.6X.

Our Neutral recommendation indicates that the stock will perform in-line with the market. Our \$56 price target reflects 10.4X forward 12-months earnings.

The table below shows summary valuation data for CAH.

Valuation Multiples - CAH					
		Stock	Sub-Industry	Sector	S&P 500
P/E F12M	Current	9.89	19.09	22.37	22.77
	5-Year High	16.75	19.84	23.17	22.77
	5-Year Low	7.45	13.63	15.89	15.25
	5-Year Median	11.6	16.47	18.97	17.58
P/S F12M	Current	0.1	0.37	2.82	3.66
	5-Year High	0.25	0.38	3.41	3.66
	5-Year Low	0.08	0.23	2.22	2.53
	5-Year Median	0.14	0.28	2.89	3.05
P/B TTM	Current	8.65	3.17	4.41	4.67
	5-Year High	18.25	4.73	5.07	4.67
	5-Year Low	1.97	2.54	2.94	2.83
	5-Year Median	3.58	3.42	4.3	3.74

As of 08/10/2020

Industry Analysis Zacks Industry Rank: Top 43% (109 out of 253)



Top Peers

Company (Ticker)	Rec	Rank
Herbalife LTD. (HLF)	Outperform	2
Nu Skin Enterprises, Inc. (NUS)	Outperform	1
OwensMinor, Inc. (OMI)	Outperform	2
Thermo Fisher Scientific Inc. (TMO)	Outperform	2
AmerisourceBergen Corporation (ABC)	Neutral	3
Becton, Dickinson and Company (BDX)	Neutral	3
Henry Schein, Inc. (HSIC)	Neutral	3
McKesson Corporation (MCK)	Neutral	3

Industry Comparison Industry: Medical - Dental Supplies				Industry Peers		
	CAH	X Industry	S&P 500	MCK	OMI	TMO
Zacks Recommendation (Long Term)	Neutral	-	-	Neutral	Outperform	Outperform
Zacks Rank (Short Term)	3	-	-	3	2	2
VGM Score	A	-	-	B	A	B
Market Cap	15.49 B	2.43 B	23.56 B	24.72 B	878.27 M	162.25 B
# of Analysts	8	5	14	9	3	8
Dividend Yield	3.66%	0.00%	1.71%	1.08%	0.07%	0.21%
Value Score	B	-	-	B	A	C
Cash/Price	0.18	0.06	0.07	0.11	0.12	0.04
EV/EBITDA	-7.43	15.13	13.39	12.28	9.92	25.21
PEG Ratio	1.60	3.14	2.92	1.65	0.39	1.83
Price/Book (P/B)	8.65	4.44	3.18	4.37	2.20	5.43
Price/Cash Flow (P/CF)	6.15	15.99	12.69	7.14	4.64	22.68
P/E (F1)	9.88	34.51	22.16	10.07	12.52	27.43
Price/Sales (P/S)	0.10	2.52	2.55	0.11	0.10	6.18
Earnings Yield	10.12%	2.26%	4.33%	9.93%	7.99%	3.64%
Debt/Equity	3.78	0.33	0.77	1.42	3.51	0.69
Cash Flow (\$/share)	8.62	1.35	6.94	21.35	2.97	18.08
Growth Score	B	-	-	C	A	B
Hist. EPS Growth (3-5 yrs)	1.54%	9.48%	10.41%	4.38%	-27.98%	14.10%
Proj. EPS Growth (F1/F0)	-1.44%	-3.46%	-6.51%	1.20%	96.43%	21.09%
Curr. Cash Flow Growth	-2.74%	3.87%	5.26%	-33.76%	-69.53%	6.99%
Hist. Cash Flow Growth (3-5 yrs)	5.57%	12.37%	8.55%	-0.50%	1.47%	10.08%
Current Ratio	1.10	1.47	1.34	1.00	1.63	2.62
Debt/Capital	79.06%	32.96%	44.59%	62.54%	77.83%	40.86%
Net Margin	-2.42%	0.40%	10.13%	0.40%	-1.23%	14.12%
Return on Equity	130.94%	11.51%	14.59%	42.33%	9.31%	18.18%
Sales/Assets	3.77	1.02	0.51	3.87	2.40	0.45
Proj. Sales Growth (F1/F0)	4.16%	0.00%	-1.54%	3.41%	-14.16%	9.77%
Momentum Score	B	-	-	A	A	B
Daily Price Chg	0.91%	0.00%	0.91%	0.26%	8.00%	-1.01%
1 Week Price Chg	-3.73%	1.74%	2.30%	1.23%	-20.71%	0.09%
4 Week Price Chg	6.40%	5.11%	8.54%	5.11%	87.09%	8.24%
12 Week Price Chg	1.63%	12.14%	13.68%	6.81%	80.95%	18.21%
52 Week Price Chg	21.20%	14.31%	3.71%	6.80%	186.28%	50.79%
20 Day Average Volume	2,310,779	529,605	2,015,804	977,085	5,745,379	1,227,439
(F1) EPS Est 1 week change	2.96%	0.00%	0.00%	0.64%	1.54%	0.00%
(F1) EPS Est 4 week change	2.00%	0.32%	1.67%	5.36%	111.54%	17.49%
(F1) EPS Est 12 week change	1.98%	0.11%	2.27%	0.22%	111.54%	25.61%
(Q1) EPS Est Mthly Chg	-1.31%	0.00%	0.67%	20.79%	52.38%	30.04%

Zacks Stock Rating System

We offer two rating systems that take into account investors' holding horizons: Zacks Rank and Zacks Recommendation. Each provides valuable insights into the future profitability of the stock and can be used separately or in combination with each other depending on your investment style.

Zacks Recommendation

The Zacks Recommendation aims to predict performance over the next 6 to 12 months. The foundation for the quantitatively determined Zacks Recommendation is trends in the company's estimate revisions and earnings outlook. The Zacks Recommendation is broken down into 3 Levels; Outperform, Neutral and Underperform. Unlike many Wall Street firms, we have an excellent balance between the number of Outperform and Neutral recommendations. Our team of 70 analysts are fully versed in the benefits of earnings estimate revisions and how that is harnessed through the Zacks quantitative rating system. But we have given our analysts the ability to override the Zacks Recommendation for the 1200 stocks that they follow. The reason for the analyst over-rides is that there are often factors such as valuation, industry conditions and management effectiveness that a trained investment professional can spot better than a quantitative model.

Zacks Rank

The Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon. The underlying driver for the quantitatively-determined Zacks Rank is the same as the Zacks Recommendation, and reflects trends in earnings estimate revisions.

Zacks Style Scores

The Zacks Style Score is as a complementary indicator to the Zacks rating system, giving investors a way to focus on the highest rated stocks that best fit their own stock picking preferences.

Academic research has proven that stocks with the best Value, Growth and Momentum characteristics outperform the market. The Zacks Style Scores rate stocks on each of these individual styles and assigns a rating of A, B, C, D and F. We also produce the VGM Score (V for Value, G for Growth and M for Momentum), which combines the weighted average of the individual Style Scores into one score. This is perfectly suited for those who want their stocks to have the best scores across the board.

Value Score	B
Growth Score	B
Momentum Score	B
VGM Score	A

As an investor, you want to buy stocks with the highest probability of success. That means buying stocks with a Zacks Recommendation of Outperform, which also has a Style Score of an A or a B.

Disclosures

This report contains independent commentary to be used for informational purposes only. The analysts contributing to this report do not hold any shares of this stock. The analysts contributing to this report do not serve on the board of the company that issued this stock. The EPS and revenue forecasts are the Zacks Consensus estimates, unless indicated otherwise on the reports first page. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts personal views as to the subject securities and issuers. ZIR certifies that no part of the analysts compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report.

Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Any opinions expressed herein are subject to change.

ZIR is not an investment advisor and the report should not be construed as advice designed to meet the particular investment needs of any investor. Prior to making any investment decision, you are advised to consult with your broker, investment advisor, or other appropriate tax or financial professional to determine the suitability of any investment. This report and others like it are published regularly and not in response to episodic market activity or events affecting the securities industry.

This report is not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. ZIR or its officers, employees or customers may have a position long or short in the securities mentioned and buy or sell the securities from time to time. ZIR is not a broker-dealer. ZIR may enter into arms-length agreements with broker-dealers to provide this research to their clients. Zacks and its staff are not involved in investment banking activities for the stock issuer covered in this report.

ZIR uses the following rating system for the securities it covers. **Outperform-** ZIR expects that the subject company will outperform the broader U.S. equities markets over the next six to twelve months. **Neutral-** ZIR expects that the company will perform in line with the broader U.S. equities markets over the next six to twelve months. **Underperform-** ZIR expects the company will underperform the broader U.S. equities markets over the next six to twelve months.

No part of this report can be reprinted, republished or transmitted electronically without the prior written authorization of ZIR.